Tillman Gerngross (Craig F. Walker/The Boston Globe via Getty Images)
After raising more than $750M in quick Covid cash, Tillman Gerngross is on his way out of troubled Adagio
The renowned antibody expert Tillman Gerngross founded Adagio in the frantic early days of the pandemic with a mission to come up with a groundbreaking antibody to fight Covid-19. The first $50 million was committed within 24 hours of his first calls. His biotech went public last summer at $17 a share — after raising $470 million from the VCs — in the middle of a biotech boom and quickly more than tripled in value, spiking in a second big wave as Omicron stoked fresh fears of a tsunami of cases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
